19th World Conference on Lung Cancer
Meet with Q2 Solutions at the 2018 World Conference on Lung Cancer and learn how our end-to-end precision medicine services can help you develop groundbreaking precision-targeted therapies
About This EventThrough Q2 Solutions’ Oncology Center of Excellence, our experts in biomarker discovery are providing a better understanding of therapeutic targets, molecular signaling, drug biology and patient response.
Our genomics capabilities enable us to partner with you in identifying predictive biomarkers and patients who may respond most appropriately to a particular therapeutic, thereby reducing development costs and timelines, while demonstrating the safety and efficacy of your therapeutic products.
Q2 Solutions’ scientific experts can help you develop translational design strategies to identify, develop assays, and screen multiple biomarkers in parallel, so the most relevant ones can be identified sooner and get you to proof of concept as early as possible.
We are committed to delivering valuable informative data to your study through carefully orchestrated analyses, to help you choose platforms and assays that will distinctly fit your lung cancer study needs. We offer tailored solutions for challenging specimens such as whole blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. Q2 Solutions utilizes a wide array of technology platforms, so that we can determine exactly what works best for you without sacrificing quality or efficiency.
Schedule a meeting with Q2 Solutions at this year’s World Conference on Lung Cancer to explore how our genomic know-how® can help you determine the best methods to obtain the data you need to improve your lung cancer clinical outcomes.
We look forward to meeting you in Toronto.